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TNF-related apoptosis inducing ligand (TRAIL) is an intensively studied cytokine, in particular for its anticancer activity. The
discovery that conjunctival sac fluid contains extremely high levels of soluble TRAIL as compared to other body fluids suggested
important implications in the context of the immunological surveillance of the eye, in particular of the anterior surface. In this
review, we discuss the potential physiopathologic and therapeutic role of the TRAIL/TRAIL receptor system in a variety of ocular
cancers. Moreover, since an increasing amount of data has indicated the important biological activities of the TRAIL/TRAIL
receptor systems also in a completely different pathologic context such as diabetes mellitus, in the second part of this review we
summarize the currently available data on the involvement of TRAIL in the ocular complications of diabetes mellitus as modulator
of the inflammatory and angiogenic response in the eye.
1. The TRAIL/TRAIL Receptor System
TNF-related apoptosis inducing ligand (TRAIL), also known
as Apo2 ligand or TNFSF10, was originally discovered
independently by Ashkenazi’s group at Genentech [1] and
Goodwin’s group at Immunex [2] almost 20 years ago.
Subsequently, the complex system of transmembrane TRAIL
receptors was identified and it resulted to be composed
of TRAIL-R1/death receptor 4, TRAIL-R2/death receptor 5,
TRAIL-R3/decoy receptor 1, and TRAIL-R4/decoy receptor
2 [3]. Similarly to other members of the TNF superfamily,
TRAIL acts as homotrimeric molecule, but it has the unique
property of containing a central zinc atom at the trimer
interface, which is important for the solubility, stability, and
biological activity of TRAIL.
The first and best characterized activity of TRAIL is
to promote apoptosis in a variety of cancer cell types by
interacting with the so-called death receptors TRAIL-R1
and TRAIL-R2 [3]. On the other hand, the two additional
transmembrane receptors TRAIL-R3 and TRAIL-R4 as well
as the soluble receptor osteoprotegerin (OPG) have been
proposed to act as decoy or regulatory receptors [4, 5]. The
biological activity of TRAIL on cancer cells is mediated by
the activation of the extrinsic pathway of apoptosis induced
by clustering (homotrimerization) of TRAIL-R1 or TRAIL-
R2 at the cell surface level. This event promotes receptor
binding to the adaptor protein Fas-associated death domain
(FADD), which in turn recruits the initiator caspases 8
and 10 and leads to the assembling of the death-inducing
signaling complex (DISC). DISC formation is modulated by
several inhibitory mechanisms, such as (i) at intracellular
level by the caspases 8/10 inhibitor c-FLIP, which directly
interferes with receptor activation; (ii) at membrane level,
due to the role of the decoy receptors TRAIL-R3 and TRAIL-
R4, which can heterotrimerize with TRAIL-R1 and TRAIL-
R2 and attenuate, or even neutralize, the proapoptotic signal.
Additional mechanisms of regulation of TRAIL-mediated
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apoptosis have been discovered and consist in posttransla-
tionalmodifications of TRAIL-R1 andTRAIL-R2, subsequent
to glycosylation and palmitoylation [6]. Also the lectin
galectin-3, which recognizes multiple N-acetyllactosamine
sequences, when highly expressed shows the property to
immobilize death receptors by trapping them in a nanocluster
lattice, blocking DISC formation [7].
In spite of its initial characterization in the cancer biology
field, our group have provided robust experimental evidence
that TRAIL can drive prosurvival and/or proliferative effects
and can modulate differentiation in normal cell types such as
human intestinal cells [8], bone marrow multipotent stromal
cells [9], myeloid cells [10–12], and osteoclastic cells [13,
14]. These trophic effects of TRAIL are mediated by the
activation of the PI3K/Akt and ERK pathways [15, 16] and
of the transcription factor NF-kB [17, 18] in a cell type
specific context. Therefore, the biologic outcome of TRAIL
stimulation seems to be determined in each cell type by
the balance of different elements, comprising transmembrane
receptor expression (including density and localization), and
intracellular components that, eventually, could switch the
cell phenotype either from apoptotic-prone to apoptotic-
resistant or vice versa [19]. For instance, sensitization to
TRAIL-induced apoptosis can also be derived from the
activation of the p53 pathway. Indeed, several studies have
shown that activation of the p53 pathway elicited by the
nongenotoxic small molecule inhibitor of MDM2 Nutlin-
3 upregulates the expression of TRAIL-R2 [20, 21], which
in turn can be sensitized to TRAIL-mediated apoptosis
[22]. Interestingly, however, the combination of Nutlin-3 and
recombinant TRAIL is much less toxic in normal cells with
respect to cancer cells, further underlining the complexity of
the regulation of TRAIL biological effects at the intracellular
level.
2. TRAIL Expression in Cornea and in
Conjunctival Sac
Significant levels of TRAIL transcripts and proteins have
been detected in many human tissues [23] including normal
epithelia such as skin [24, 25], buccal mucosa [26], intestinal
mucosa [8], and corneal and conjunctival epithelia [27–29].
In particular, expression of TRAIL has been previously docu-
mented in human corneal and conjunctival epithelia by in situ
immunohistochemistry using a monoclonal antibody which
is highly specific for TRAIL [28]. While corneal epithelium
was strongly positive for TRAIL expression with a more
intense TRAIL immunostaining observed in the basal layers,
conjunctival epithelium expressed TRAIL but at a lower
intensity with respect to the corneal epithelium [28]. On the
other hand, no TRAIL immunostaining was documented in
sclera [28]. The immunohistochemistry data were confirmed
by flow cytometry in primary corneal epithelial cells and
were obtained from patients undergoing photorefractive
keratectomy [28]. Such a widespread distribution of TRAIL
expression differs from that of most TNF family members
and is in line with the in vitro data, showing that TRAIL is not
cytotoxic onmost normal tissues in vivo. Of note, in the same
study [28], we have also demonstrated that the conjunctival
sac fluid contained the highest amount of soluble TRAIL ever
measured in a body fluid. Indeed, the mean level of soluble
TRAIL detected in the conjunctival sac fluid was 26 ng/mL,
>200-fold greater than that found in human serum/plasma
(range of 55 to 110 pg/mL). It is particularly remarkable that
the concentrations of TRAIL in the conjunctival sac fluid
were in range able to significantly induce apoptosis in vitro
in B lymphoma cells [28].
3. TRAIL and Ocular Tumors
In spite of the lack of immune cells, the eye is refractory to
the development of tumors (both primary intraocular tumors
and tumors metastasizing from distant sites). In particular,
corneal and conjunctival tumors are extremely rare [30].
Thus, a reasonable hypothesis based on the extremely high
levels of TRAIL in the conjunctival sac fluid [28] is that
TRAIL is involved in the antitumoral surveillance of the
anterior epithelium of the ocular globe. In this respect, it
is interesting to analyze the available data concerning the
potential susceptibility of ocular tumors to TRAIL-based
therapy.
3.1. Rhabdomyosarcoma. Rhabdomyosarcoma (RMS) repre-
sents the most common soft tissue sarcoma in children
and nearly 35–40% of RMS occurs in the head and in the
neck including orbital tissue. This highly malignant tumor
is insensitive to chemotherapy alone and, thus, TRAIL rep-
resents a promising candidate for new options in combined
therapy. Indeed, when used together with cisplatin, TRAIL
has shown synergistic cytotoxic effects on RMS cells [31],
which was related to the downregulation of mitochondrial
membrane potential in RMS cells. TRAIL also showed addi-
tive cytotoxic effects on RMS cells when used in combination
with doxorubicin [32]. Finally, TRAIL was able to restore
the susceptibility of melphalan-resistant RMS tumor cells to
cytotoxicity mediated by caspases 2 and 3 [33]. Overall, these
data clearly indicate that TRAIL is potentially active in RMS
in combination with different chemotherapeutic drugs which
are currently employed in the treatment of RMS (Figure 1).
3.2. Uveal Melanoma. Uveal melanoma is a common oph-
thalmic malignancy in human which is prone to metas-
tatize to other organ such as liver [34]. The prognosis of
patients carrying uveal melanoma is quite poor and themean
overall survival is generally 2–8 months, and the survival
of patients that suffer from metastasis benefits little from
the current treatments, including photocoagulation, surgery,
and radiotherapy. Therefore, alternative therapeutic options
are urgently needed to treat malignant uveal melanoma.
Among the different experimental approaches explored,
several studies have investigated the potential therapeutic
effects of TRAIL (Figure 2). In this respect, it has been
proposed that radiotherapy might represent an important
tool for sensitizing uveal melanoma to TRAIL cytotoxicity
[35] and the study of Ren et al. [36] was the first one showing
a potential efficacy of TRAIL in promoting apoptosis of
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Figure 1: Synergic therapeutic approaches between TRAIL and chemotherapeutic drugs on rhabdomyosarcoma (RMS). Antitumor therapies
based on the combination of standard chemotherapywithTRAIL treatment can lead to improvedRMScell apoptosis and/or to the overcoming
of chemotherapy resistance. TRAIL-R, TRAIL receptors.
uveal melanoma cells. Moreover, cycloheximide exerted a
profound effect in enhancing TRAIL-induced apoptosis in
uveal melanoma cell lines, including metastatic cell lines
[36]. Similarly, interferon-𝛽 also produced an enhancement
of TRAIL-induced apoptosis even in melanoma cell lines
that were previously shown to be resistant [36]. These
data might also account for the finding that, in preclinical
studies, interferon- (INF-) 𝛽 induced (i) the serum release of
TRAIL and (ii) cell apoptosis and antitumor effects against
melanoma [37]. More recently, an approach based on the
adenovirus-based TRAIL expression has been proposed to
treat malignant uveal melanoma with high cell specificity
[38]. Interestingly, in a recent study, it has also been shown
that while TRAIL-R1/DR4 and TRAIL-R2/DR5 methyla-
tion is not frequent in cutaneous melanoma, it was very
frequent in uveal melanoma [39]. Consistently, the same
group of investigators has demonstrated that class I-specific
histone deacetylase inhibitor MS-275 overrides TRAIL resis-
tance in melanoma cells by downregulating c-FLIP [40].
Moreover, different studies have shown that sensitivity to
TRAIL-induced apoptosis of cultured melanoma cells may
be restored/enhanced by exposure to 2-deoxy-D-glucose
(2-DG) [41, 42], aminooxyacetate (AOA), an inhibitor
of glutamate-dependent transaminase [43], or cyclolignan
picropodophyllin (PPP), a specific inhibitor of IGF-1R kinase
activity [44].
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Figure 2: Potential TRAIL-mediated therapeutic approaches to target uveal melanoma cells. Different agents such as radiotherapy,
cycloheximide, interferon-beta (IFN-𝛽), class-I specific histone deacetylase inhibitor MS-275, 2-deoxy-D-glucose (2-DG), the glutamate-
dependent transaminase inhibitor aminooxyacetate (AOA), and the specific IGF-1R kinase inhibitor cyclolignan picropodophyllin (PPP)
may sensitize uveal melanoma cells to TRAIL-mediated apoptosis or enhance TRAIL cytotoxicity. TRAIL-R, TRAIL receptors.
3.3. Orbital Lymphoma. Orbital lymphoma accounts for 10%
of the orbital malignant tumors [45, 46]. Interestingly, it has
been shown that the combination of irradiation and TRAIL
synergistically induced apoptosis in malignant lymphatic cell
lines enhances the efficacy of combined tumor therapy in
the radiotherapy-tolerant lymphatic cells with Bcl-2 overex-
pression [46]. Of note, Unnithan and Macklis documented
an increase of TRAIL expression in patients treated with
radiation for lymphoma [47]. Moreover, a number of studies
of our group and other groups of investigators have addressed
the role of individual TRAIL receptor in mediating the
proapoptotic activity of ionizing radiation in different types
of malignancies, including lymphoblastic cells, document-
ing that TRAIL-R1/DR4 represents the principal receptor
involved in mediating the proapoptotic activity of ionizing
radiation [48–51].
4. TRAIL and Ocular Complications of
Diabetes Mellitus
Beside the well-studied role of TRAIL in oncologic settings,
an increasing amount of data has indicated the important bio-
logical activities of the TRAIL/TRAIL receptor systems also
in diabetes mellitus [52–54]. For the purpose of the present
review, we summarize the currently available data on the
involvement of TRAIL in the ocular complications associated
to diabetes mellitus [55].
4.1. Proliferative Diabetic Retinopathy. Proliferative diabetic
retinopathy, as well as other proliferative retinopathies, is
caused by widespread ischemia of the inner retinal layers,
secondary to closure of the parts of the retinal capillary bed,
leading to new vessel formation in the retina. Proliferative
diabetic retinopathy is considered a wound healing-like
response in which neovascularization is accompanied by
an influx of inflammatory cells and the development of
myofibroblasts, with fibrovascular contraction causing hem-
orrhages, retinal detachment, and blindness [55]. Vascular
endothelial growth factor (VEGF) and other proangiogenic
factors produced by the ischemic retina are considered to
be the major causal growth factors in the neovascularization
process. However, negative regulators of angiogenesis, such
as pigment-epithelium derived factors (PEDF), might also
interfere with the VEGF-angiogenesis by downregulating
the PI3K/Akt pathway. In this context, an interesting study
demonstrated that PEDF, which is an intrinsic antiangio-
genic factor and a potential antitumor agent, increases the
expression of TRAIL [56].Moreover, a recent study suggested
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that TRAIL might play an important role in restraining
endothelial cell proliferation in the retina, as: (i) TRAIL
deficient mice exhibited delayed regression of retinal neovas-
cularization and (ii) recombinant TRAIL-induced apoptosis
of retinal endothelial cells [57]. In this respect studies by
Secchiero’s group [58, 59] and other investigators [60] have
suggested that TRAIL plays an important role in modulating
vascular function andmight have prognostic value in diabetic
patients affected by cardiovascular complications [61–63].
Therefore, the high levels of soluble TRAIL documented in
the conjunctival sac fluid may suggest an important role of
TRAIL also in modulating the inflammatory and angiogenic
response in the eye [64]. In this respect, we have also
documented that the levels of TRAIL in the conjunctival
sac fluid are significantly decreased in patients affected
by proliferative retinopathy [29]. Although the relationship
between external soluble TRAIL (released in the conjunctival
sac fluid) and internal TRAIL (expressed in the retina or
vitreous body) is not known, these data strengthen the notion
that TRAIL plays an important anti-inflammatory role and
antiangiogenic role for the anatomic and functional stability
and for the safety of the ocular surfaces. Thus, it is plausible
to suppose that a decreased production and/or release of
TRAIL might contribute to worsening proliferative diabetic
retinopathy by reducing the degree of apoptosis in retinal
endothelial cells. In line with a potential role of TRAIL in
mediating antiangiogenic activity, it has been shown that
TRAIL might play an important role also in the regulation
of retinal neovascularization (RNV) [57]. In particular, while
RNV naturally regressed in wild-type mice, TRAIL(−/−)
mice continued to display significantly high levels of RNV
attributed to a significant decrease in neovascular tuft cells
undergoing apoptosis. Of interest, the antiangiogenic activity
of TRAIL has been suggested also in recent studies in patients
affected by colon cancer under treatment with bevacizumab
[65, 66] and confirmed in in vitro studies [67, 68].
4.2. Age-Related Macular Degeneration. An important role
of apoptosis driven by TRAIL also in age-related macular
degeneration (AMD), an important ocular disorder which
represents a leading cause of irreversible vision loss in elderly,
with diabetes playing a role as risk factor for AMD, has
been proposed. Indeed, in a large cohort study consisting of
1826 subjects which included 300 cases with AMD, a signif-
icant association between TRAIL-R1 TNFRSF10-LOC389641
rs13278062 and increased risk of late macular age-related
degeneration was observed [69]. Moreover, Anand et al. [70]
have found significantly lower levels of TRAIL-R3 in serum
samples of patients affected by AMD compared to controls.
Since TRAIL-R3 is believed to act as dominant-negative
receptor, the authors suggest that the low levels of TRAIL-
R3 in these patients may increase the amount of TRAIL
interacting with the proapoptotic receptors (TRAIL-R1 and
TRAIL-R2), thus resulting in enhanced TRAIL apoptosis of
photoreceptors and retinal pigment epithelium cells, which
are well known phenomena involved in the pathogenesis of
AMD [71].
5. Conclusions
The TRAIL/TRAIL-R system plays an important role in
relevant ocular pathologic settings, such as cancers and
major diabetic complications (id, retinopathy, and macular
degeneration). A central finding was the discovery that the
expression/release of TRAIL in different ocular tissues is
extremely elevated. Thus, TRAIL likely represents a major
actor involved in the immune surveillance against ocular
tumours as well as modulator of the inflammatory and
angiogenic response in the eye. Indeed, besides its well
known ability to induce apoptosis in tumor cells, a role
of TRAIL/TRAIL receptors in endothelial cell biology has
recently emerged, revealing a trophic effect of TRAIL on
primary normal endothelial cells and antiangiogenic activity
in a variety of pathologic experimental conditions. The
antiangiogenic function of TRAIL might represent a com-
mon link between the apparently distinct roles of TRAIL in
cancer and in endothelial cell biology.
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